Medical history of cardiovascular events
| . | ASPEN cohort 1 WM . | ALPINE R/R CLL/SLL . | Pooled analysis ASPEN/ALPINE . | Pooled analysis B-cell malignancies . | |||
|---|---|---|---|---|---|---|---|
| Zanubrutinib (n = 101) . | Ibrutinib (n = 98) . | Zanubrutinib (n = 324) . | Ibrutinib (n = 324) . | Zanubrutinib (N = 425) . | Ibrutinib (N = 422) . | Zanubrutinib (N = 1550) . | |
| Medical history of cardiovascular events, n (%) | |||||||
| Atrial fibrillation/flutter | 10 (9.9) | 8 (8.2) | 19 (5.9) | 18 (5.6) | 29 (6.8) | 26 (6.2) | 101 (6.5) |
| Ventricular arrhythmia∗ | 1 (1.0) | 0 | 2 (0.6) | 1 (0.3) | 3 (0.7)† | 1 (0.2)‡ | 14 (0.9) |
| Hypertension§ | 39 (38.6) | 45 (45.9) | 165 (50.9) | 162 (50.0) | 204 (48.0) | 207 (49.1) | 668 (43.1) |
| . | ASPEN cohort 1 WM . | ALPINE R/R CLL/SLL . | Pooled analysis ASPEN/ALPINE . | Pooled analysis B-cell malignancies . | |||
|---|---|---|---|---|---|---|---|
| Zanubrutinib (n = 101) . | Ibrutinib (n = 98) . | Zanubrutinib (n = 324) . | Ibrutinib (n = 324) . | Zanubrutinib (N = 425) . | Ibrutinib (N = 422) . | Zanubrutinib (N = 1550) . | |
| Medical history of cardiovascular events, n (%) | |||||||
| Atrial fibrillation/flutter | 10 (9.9) | 8 (8.2) | 19 (5.9) | 18 (5.6) | 29 (6.8) | 26 (6.2) | 101 (6.5) |
| Ventricular arrhythmia∗ | 1 (1.0) | 0 | 2 (0.6) | 1 (0.3) | 3 (0.7)† | 1 (0.2)‡ | 14 (0.9) |
| Hypertension§ | 39 (38.6) | 45 (45.9) | 165 (50.9) | 162 (50.0) | 204 (48.0) | 207 (49.1) | 668 (43.1) |
Any-grade ventricular arrhythmia.
Includes 2 events of ventricular extrasystoles and 1 event of ventricular tachycardia.
Includes 1 event of ventricular extrasystoles.
Includes hypertension, essential hypertension, preeclampsia, hypertensive cardiomyopathy, hypertensive retinopathy, hypertension neonatal, blood pressure increased, orthostatic hypertension, and hypertensive heart disease.